Martin WD - Search Results

1

CD1d1 mutant mice are deficient in natural T cells that promptly produce IL-4.

Mendiratta SK, Martin WD, Hong S, Boesteanu A, Joyce S, Van Kaer L. Mendiratta SK, et al. Among authors: martin wd. Immunity. 1997 Apr;6(4):469-77. doi: 10.1016/s1074-7613(00)80290-3. Immunity. 1997. PMID: 9133426 Free article.

2

H2-M mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection.

Martin WD, Hicks GG, Mendiratta SK, Leva HI, Ruley HE, Van Kaer L. Martin WD, et al. Cell. 1996 Feb 23;84(4):543-50. doi: 10.1016/s0092-8674(00)81030-2. Cell. 1996. PMID: 8598041 Free article.

3

The imprint of intrathymic self-peptides on the mature T cell receptor repertoire.

Sant'Angelo DB, Waterbury PG, Cohen BE, Martin WD, Van Kaer L, Hayday AC, Janeway CA Jr. Sant'Angelo DB, et al. Among authors: martin wd. Immunity. 1997 Oct;7(4):517-24. doi: 10.1016/s1074-7613(00)80373-8. Immunity. 1997. PMID: 9354472 Free article.

4

Peptide dependency of alloreactive CD4+ T cell responses.

Mendiratta SK, Kovalik JP, Hong S, Singh N, Martin WD, Van Kaer L. Mendiratta SK, et al. Among authors: martin wd. Int Immunol. 1999 Mar;11(3):351-60. doi: 10.1093/intimm/11.3.351. Int Immunol. 1999. PMID: 10221647

5

The alloreactive and self-restricted CD4+ T cell response directed against a single MHC class II/peptide combination.

Kovalik JP, Singh N, Mendiratta SK, Martin WD, Ignatowicz L, Van Kaer L. Kovalik JP, et al. Among authors: martin wd. J Immunol. 2000 Aug 1;165(3):1285-93. doi: 10.4049/jimmunol.165.3.1285. J Immunol. 2000. PMID: 10903728

6

MHC class II expression in double mutant mice lacking invariant chain and DM functions.

Kenty G, Martin WD, Van Kaer L, Bikoff EK. Kenty G, et al. Among authors: martin wd. J Immunol. 1998 Jan 15;160(2):606-14. J Immunol. 1998. PMID: 9551894

7

A critical, invariant chain-independent role for H2-M in antigen presentation.

Swier K, Brown DR, Bird JJ, Martin WD, Van Kaer L, Reiner SL. Swier K, et al. Among authors: martin wd. J Immunol. 1998 Jan 15;160(2):540-4. J Immunol. 1998. PMID: 9551884

8

In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies.

Mattei AE, Gutierrez AH, Seshadri S, Tivin J, Ardito M, Rosenberg AS, Martin WD, De Groot AS. Mattei AE, et al. Among authors: martin wd. MAbs. 2024 Jan-Dec;16(1):2333729. doi: 10.1080/19420862.2024.2333729. Epub 2024 Mar 27. MAbs. 2024. PMID: 38536724 Free PMC article.

9

Neoadjuvant personalized cancer vaccines: the final frontier?

Richard G, Ruggiero N, Steinberg GD, Martin WD, De Groot AS. Richard G, et al. Among authors: martin wd. Expert Rev Vaccines. 2024 Jan-Dec;23(1):205-212. doi: 10.1080/14760584.2024.2303015. Epub 2024 Jan 10. Expert Rev Vaccines. 2024. PMID: 38189107 Free article. Review.

10

Does human homology reduce the potential immunogenicity of non-antibody scaffolds?

De Groot AS, Khan S, Mattei AE, Lelias S, Martin WD. De Groot AS, et al. Among authors: martin wd. Front Immunol. 2023 Nov 7;14:1215939. doi: 10.3389/fimmu.2023.1215939. eCollection 2023. Front Immunol. 2023. PMID: 38022550 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

93 results

Search Page